Clinical Trial Update: Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase II clinical trial evaluating a combination of chemotherapy, a PD-1 inhibitor, and autologous CIK cell immunotherapy for metastatic non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Autologous cytokine-induced killer (CIK) cell immunotherapy (CIK cell immunotherapy)
• Chemotherapy regimen (unspecified)
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer Metastatic, First-line Treatment | Phase 2 | Status: ACTIVE_NOT_RECRUITING